Researchers observed an increase in both CXCR4 and CD5 levels as the cells progressed to later stages of the cell cycle, particularly in the S/G2/M phases.

Research found that ibrutinib reduces red blood cell aggregation in patients with chronic lymphocytic leukemia (CLL), while ...

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy, with disease progression ranging from slow and indolent to ...

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Venetoclax, a selective Bcl-2 inhibitor, has proven effective in chronic lymphocytic leukemia (CLL), but genetic mutations or ...

Expert Rev Hematol. 2013;6(4):441-449. In conclusion, although age should generally determine the goal of treatment in CLL, the patient's functional status rather than chronological age can be ...

Acalabrutinib–venetoclax with or without obinutuzumab significantly prolonged progression-free survival as compared with chemoimmunotherapy in fit patients with previously untreated CLL.

An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...

Hope is crucial for those of us with chronic lymphocytic leukemia, or any cancer, helping us navigate the disease's challenges. Regardless of the stage when a cancer is diagnosed, finding and ...

Chronic lymphocytic leukemia (CLL) starts in bone marrow, the soft inner part of your bones. There are some key differences that set CLL apart from other types of leukemia, such as ALL (acute ...

Chronic lymphocytic leukemia (CLL) is usually a slow-growing blood cancer. Most people with CLL don’t notice any problems in the early stages of the disease. “In fact, we can do what we call ...